[go: up one dir, main page]

MX9604985A - Cardiotropina y usos de la misma. - Google Patents

Cardiotropina y usos de la misma.

Info

Publication number
MX9604985A
MX9604985A MX9604985A MX9604985A MX9604985A MX 9604985 A MX9604985 A MX 9604985A MX 9604985 A MX9604985 A MX 9604985A MX 9604985 A MX9604985 A MX 9604985A MX 9604985 A MX9604985 A MX 9604985A
Authority
MX
Mexico
Prior art keywords
chf
disorders
cardiotrophin
neurological
uses therefor
Prior art date
Application number
MX9604985A
Other languages
English (en)
Inventor
Joffre Baker
Kenneth Chien
Kathleen King
Diane Pennica
William Wood
Original Assignee
Genentech Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/233,609 external-priority patent/US5534615A/en
Application filed by Genentech Inc, Univ California filed Critical Genentech Inc
Publication of MX9604985A publication Critical patent/MX9604985A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion se refiere a un factor de hipertrofia cardiaca (CHF), a un ADN aislado que codifica para CHF y a métodos sintéticos o recombinantes para preparar CHF. Estas moléculas tienen influencia sobre la actividad hipertrofica y la actividad neurologica. De conformidad con ello, estos compuestos o sus antagonistas se pueden utilizar para el tratamiento de insuficiencia cardiaca, trastornos arritmicos, trastornos inotropicos y trastornos neurologicos.
MX9604985A 1994-04-25 1995-04-06 Cardiotropina y usos de la misma. MX9604985A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/233,609 US5534615A (en) 1994-04-25 1994-04-25 Cardiac hypertrophy factor and uses therefor
US08/286,304 US5571893A (en) 1994-04-25 1994-08-05 Cardiac hypertrophy factor
PCT/US1995/004467 WO1995029237A1 (en) 1994-04-25 1995-04-06 Cardiotrophin and uses therefor

Publications (1)

Publication Number Publication Date
MX9604985A true MX9604985A (es) 1998-05-31

Family

ID=26927082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9604985A MX9604985A (es) 1994-04-25 1995-04-06 Cardiotropina y usos de la misma.

Country Status (10)

Country Link
US (5) US5571675A (es)
EP (1) EP0755446B1 (es)
JP (1) JP3906314B2 (es)
AT (1) ATE339503T1 (es)
CA (1) CA2188017C (es)
DE (1) DE69535221T2 (es)
DK (1) DK0755446T3 (es)
ES (1) ES2276393T3 (es)
MX (1) MX9604985A (es)
WO (1) WO1995029237A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288034B1 (en) * 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US7258983B2 (en) * 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US5869274A (en) * 1995-08-09 1999-02-09 Zymed Laboratories, Inc. Immuno-histochemical method that reduces background staining
AU768995B2 (en) * 1996-02-14 2004-01-15 Genentech Inc. Cardiotrophin and uses therefor
IL125548A (en) * 1996-02-14 2004-07-25 Genentech Inc Cardiotrophin-1 compositions and uses thereof for treatment of mammalian cells
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
CA2304254C (en) 1997-06-11 2012-05-22 Hans Christian Thogersen Trimerising module
US6610480B1 (en) * 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
US6875567B1 (en) * 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
DK2016951T3 (da) 1998-03-17 2012-09-24 Genentech Inc VEGF- og BMP1-homologe polypeptider
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
CA2354375A1 (en) * 1999-01-21 2000-07-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU3871200A (en) * 1999-03-09 2000-09-28 Atlantic Biopharmaceuticals, Inc. Expression of human alpha-fetoprotein in mammalian cells
IL147442A0 (en) * 1999-07-12 2002-08-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
AU3075701A (en) * 2000-02-11 2001-08-20 Genentech Inc. Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (en) 2000-06-23 2011-01-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2002312411A1 (en) * 2001-06-07 2002-12-16 Proligo Llc Microcalorimetric detection of analytes and binding events
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ES2200646B1 (es) 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
JP4838710B2 (ja) * 2003-06-25 2011-12-14 オタワ ヘルス リサーチ インスティテュート カルジオトロフィンの幹細胞増殖調節への使用
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
WO2009036349A1 (en) * 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
CA2777162A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
JP2014507423A (ja) * 2011-02-01 2014-03-27 フェイト セラピューティクス，インコーポレイテッド 増強された治療剤のためのカルジオトロフィン関連分子

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552071A (en) * 1978-06-21 1980-01-09 Kuzumaki Ringiyou Kk Turnery working method and its device
JPS5520721A (en) * 1978-07-31 1980-02-14 Nippi:Kk Separation of biologically active material from hematopiesis tissue of domestic animal
US4339441A (en) * 1981-10-30 1982-07-13 Sumner M. Kalman Cardioactive factor
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4900811A (en) * 1983-07-21 1990-02-13 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0233838A3 (en) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
WO1990009399A1 (en) * 1989-02-15 1990-08-23 Ono Pharmaceutical Co., Ltd. New neurotrophic factor
US5215969A (en) * 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
JP2829755B2 (ja) * 1989-12-27 1998-12-02 株式会社第一ラジオアイソトープ研究所 抗ヒト心筋ｃプロテインモノクローナル抗体及び該抗体を産生するハイブリドーマ
JP2904935B2 (ja) * 1990-10-19 1999-06-14 武田薬品工業株式会社 神経栄養活性抑制物質
US5214031A (en) * 1990-05-09 1993-05-25 Yoko Uchida Growth-inhibitory factor obtained from human brain
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
JPH04124198A (ja) * 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
EP0563304A4 (en) * 1990-12-21 1994-09-14 Univ Case Western Reserve Neuronal cholinergic differentiation factor
EP0662092B1 (en) * 1991-04-22 2005-03-23 THE UNITED STATES OF AMERICA, represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Activity-dependent neurotrophic factor
AU2010592A (en) * 1991-05-20 1992-12-30 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
NZ243084A (en) * 1991-06-12 1995-08-28 Regeneron Pharma Production and recovery of recombinant neurotrophins, genes for a modified lamb signal sequence, fusion genes and plasmids
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
WO1994005788A1 (fr) * 1991-09-12 1994-03-17 Sumitomo Pharmaceuticals Company, Limited Peptide neurotrophique
MX9205293A (es) * 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
CA2119580A1 (en) * 1991-10-01 1993-04-15 George Cachianes Production of gpa neurotrophic factor
WO1993018065A1 (fr) * 1992-03-10 1993-09-16 Mochida Pharmaceutical Co., Ltd. Substance proteique physiologiquement active
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1993024529A1 (en) * 1992-06-04 1993-12-09 University Of Southern California Retinal pigmented epithelium derived neurotrophic factor
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor

Also Published As

Publication number Publication date
JPH09512427A (ja) 1997-12-16
US5627073A (en) 1997-05-06
ES2276393T3 (es) 2007-06-16
WO1995029237A1 (en) 1995-11-02
AU2635395A (en) 1995-11-16
ATE339503T1 (de) 2006-10-15
US5723585A (en) 1998-03-03
CA2188017C (en) 2010-09-28
DK0755446T3 (da) 2007-01-29
US5571675A (en) 1996-11-05
DE69535221T2 (de) 2007-09-13
EP0755446B1 (en) 2006-09-13
JP3906314B2 (ja) 2007-04-18
US5624806A (en) 1997-04-29
CA2188017A1 (en) 1995-11-02
AU697165B2 (en) 1998-10-01
DE69535221D1 (de) 2006-10-26
EP0755446A1 (en) 1997-01-29
US5679545A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
MX9604985A (es) Cardiotropina y usos de la misma.
BG105643A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds
EP0335637A3 (en) Nerve growth factor peptides
MX9602517A (es) Naftiloamidas como agentes del sistema nervioso central.
MY131442A (en) Excitatory amino acid receptor antagonists
ATE209492T1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
ATE113295T1 (de) Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren.
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
MY107728A (en) Substituted cyclohexanols as central nervous system agents.
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
AU7435494A (en) Neurite growth regulatory factors
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
EP0319315A3 (en) The von willebrand factor binding domain of factor viii
WO1997030146A3 (en) Cardiotrophin and uses therefor
AU2458988A (en) The preparation, by genetic manipulation, of anticoagulative protein pp4
WO1993000427A3 (en) Neurite growth regulatory factors
MY107354A (en) Substituted cyclohexenes as central nervous system agents
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
EP0273310A3 (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
HUT47976A (en) Process for producing recombinant expression dna vectors encoding isopenicillin-n-synthetase enzyme of aspergillus nidulans, as well as dna molecules
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen